Cargando…

Chemoradiotherapy in pancreatic carcinoma

Pancreatic cancer patients present late in their course and surgical resection as a modality of treatment is of limited value. Majority develop loco-regional failure and distant metastasis, therefore, adjuvant therapy comprising of radiotherapy and chemotherapy are useful treatment options to achiev...

Descripción completa

Detalles Bibliográficos
Autores principales: Pathy, Sushmita, Chander, Subhash
Formato: Texto
Lenguaje:English
Publicado: Medknow Publications 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2885880/
https://www.ncbi.nlm.nih.gov/pubmed/20596304
http://dx.doi.org/10.4103/0971-5851.60049
_version_ 1782182417783586816
author Pathy, Sushmita
Chander, Subhash
author_facet Pathy, Sushmita
Chander, Subhash
author_sort Pathy, Sushmita
collection PubMed
description Pancreatic cancer patients present late in their course and surgical resection as a modality of treatment is of limited value. Majority develop loco-regional failure and distant metastasis, therefore, adjuvant therapy comprising of radiotherapy and chemotherapy are useful treatment options to achieve higher loco-regional control. Specialized irradiation techniques like intra-operative radiotherapy that help to increase the total tumor dose have been used, however, controvertible survival benefit was observed. Various studies have shown improved median and overall survival with chemoradiotherapy for advanced unresectable pancreatic carcinoma. The role of new agents such as topoisomerase I inhibitors also needs further clinical investigations.
format Text
id pubmed-2885880
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Medknow Publications
record_format MEDLINE/PubMed
spelling pubmed-28858802010-07-01 Chemoradiotherapy in pancreatic carcinoma Pathy, Sushmita Chander, Subhash Indian J Med Paediatr Oncol Review Article Pancreatic cancer patients present late in their course and surgical resection as a modality of treatment is of limited value. Majority develop loco-regional failure and distant metastasis, therefore, adjuvant therapy comprising of radiotherapy and chemotherapy are useful treatment options to achieve higher loco-regional control. Specialized irradiation techniques like intra-operative radiotherapy that help to increase the total tumor dose have been used, however, controvertible survival benefit was observed. Various studies have shown improved median and overall survival with chemoradiotherapy for advanced unresectable pancreatic carcinoma. The role of new agents such as topoisomerase I inhibitors also needs further clinical investigations. Medknow Publications 2009 /pmc/articles/PMC2885880/ /pubmed/20596304 http://dx.doi.org/10.4103/0971-5851.60049 Text en © Indian Journal of Medical and Paediatric Oncology http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Pathy, Sushmita
Chander, Subhash
Chemoradiotherapy in pancreatic carcinoma
title Chemoradiotherapy in pancreatic carcinoma
title_full Chemoradiotherapy in pancreatic carcinoma
title_fullStr Chemoradiotherapy in pancreatic carcinoma
title_full_unstemmed Chemoradiotherapy in pancreatic carcinoma
title_short Chemoradiotherapy in pancreatic carcinoma
title_sort chemoradiotherapy in pancreatic carcinoma
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2885880/
https://www.ncbi.nlm.nih.gov/pubmed/20596304
http://dx.doi.org/10.4103/0971-5851.60049
work_keys_str_mv AT pathysushmita chemoradiotherapyinpancreaticcarcinoma
AT chandersubhash chemoradiotherapyinpancreaticcarcinoma